Comparative Pharmacology
Head-to-head clinical analysis: DEXONE 4 versus KENALOG IN ORABASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXONE 4 versus KENALOG IN ORABASE.
DEXONE 4 vs KENALOG IN ORABASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone is a long-acting glucocorticoid receptor agonist, binding to glucocorticoid response elements to modulate gene transcription, resulting in anti-inflammatory, immunosuppressive, anti-allergic, and anti-shock effects.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, suppress immune response, and inhibit fibroblast proliferation.
Oral: 0.75–9 mg/day divided every 6–12 hours; IV/IM: 0.5–9 mg/day divided every 6–12 hours.
Apply a thin layer to the affected area 2-4 times daily, after meals and at bedtime. Do not rub in; allow to form a film.
None Documented
None Documented
Terminal elimination half-life: 2-3 hours (oral); clinical effects persist longer due to glucocorticoid receptor-mediated genomic actions
Terminal half-life approximately 2-5 hours following mucosal application.
Renal excretion of metabolites (<5% unchanged drug); minor biliary/fecal elimination (<1%)
Primarily hepatic metabolism; metabolites excreted renally (~75%) and in feces (~10%).
Category C
Category C
Corticosteroid
Corticosteroid